Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q3

4572.TEDINET S100S238
Period2023-01-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥711m2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.1bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥1.2bn2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥754m2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥1.2bn2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥736m2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥1.2bn2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥779m2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥1.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥795m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.2bn2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥795m2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥4.2bnat 2023-09-30Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥4.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥376mat 2023-09-30Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥3.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥3.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-73.742023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-20.132023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-58.562022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio91.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio86.5%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥1.4bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥711m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥711m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥218m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.1bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥336m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 306
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant188201000JPY
Noncurrent liabilitiesCurrentQuarterInstant98317000JPY
LiabilitiesPrior1YearInstant624609000JPY
LiabilitiesCurrentQuarterInstant375617000JPY
Capital stockPrior1YearInstant1382246000JPY
Capital stockCurrentQuarterInstant2076474000JPY
Capital surplusPrior1YearInstant5133456000JPY
Capital surplusCurrentQuarterInstant5827683000JPY
Retained earningsPrior1YearInstant-2922490000JPY
Retained earningsCurrentQuarterInstant-4152835000JPY
Treasury stockPrior1YearInstant-222000JPY
Treasury stockCurrentQuarterInstant-222000JPY
Shareholders equityPrior1YearInstant3592988000JPY
Shareholders equityCurrentQuarterInstant3751099000JPY
Valuation difference on available for sale securitiesPrior1YearInstant-2373000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant-3024000JPY
Deferred gains or losses on hedgesPrior1YearInstant615000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant－JPY
Foreign currency translation adjustmentPrior1YearInstant33225000JPY
Foreign currency translation adjustmentCurrentQuarterInstant68543000JPY
Valuation and translation adjustmentsPrior1YearInstant31467000JPY
Valuation and translation adjustmentsCurrentQuarterInstant65518000JPY
Subscription rights to sharesPrior1YearInstant17388000JPY
Subscription rights to sharesCurrentQuarterInstant－JPY
Net assetsPrior1YearInstant3641844000JPY
Net assetsCurrentQuarterInstant3816618000JPY
Liabilities and net assetsPrior1YearInstant4266453000JPY
Liabilities and net assetsCurrentQuarterInstant4192236000JPY
Net salesPrior1YTDDuration1095607000JPY
Net salesCurrentYTDDuration711294000JPY
Cost of salesPrior1YTDDuration123674000JPY
Cost of salesCurrentYTDDuration123644000JPY
Gross profitPrior1YTDDuration971932000JPY
Gross profitCurrentYTDDuration587650000JPY
Selling general and administrative expensesPrior1YTDDuration1725638000JPY
Selling general and administrative expensesCurrentYTDDuration1789406000JPY
Operating incomePrior1YTDDuration-753705000JPY
Operating incomeCurrentYTDDuration-1201755000JPY
Interest income noiPrior1YTDDuration127000JPY
Interest income noiCurrentYTDDuration145000JPY
Dividends income noiPrior1YTDDuration307000JPY
Dividends income noiCurrentYTDDuration318000JPY
Subsidy income noi bountyPrior1YTDDuration1000000JPY
Subsidy income noi bountyCurrentYTDDuration－JPY
Foreign exchange gains noiPrior1YTDDuration20047000JPY
Foreign exchange gains noiCurrentYTDDuration6013000JPY
Other noiPrior1YTDDuration3178000JPY
Other noiCurrentYTDDuration127000JPY
Non operating incomePrior1YTDDuration24660000JPY
Non operating incomeCurrentYTDDuration6605000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass